Post Op Ocular Inflammation — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for post op ocular inflammation. 102 active patents protecting 6 drugs from 5+ originators. First major cliff: 2032. Daily refresh.

6
Approved drugs
102
Active US patents
57/100
Avg vulnerability
—
Annual revenue covered

Originators in Post Op Ocular Inflammation

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bausch Health 32 patents Generic (originally Merck/Upjohn) 29 patents Pfizer 24 patents Hisamitsu Pharmaceutical Co., Inc 14 patents Harrow Health 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating post op ocular inflammation. Each bar = one year. Y-axis scaled to peak year (34 patents).

15
27
2
28
9
29
19
30
6
32
34
33
7
34
3
36
3
37
1
39
1
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Lotemax
LOTEPREDNOL ETABONATE
 Bausch Health 32 42 — 2033-05-03
Arthrotec
Diclofenac Sodium
 Pfizer 24 73 — 2027-03-22
Decadron
dexamethasone
 Generic (originally Merck) 15 46 — 2027-12-19
Voltaren
DICLOFENAC
 Hisamitsu Pharmaceutical Co., Inc 14 57 — 2030-04-23
Cortef
hydrocortisone
 Generic (originally Merck/Upjohn) 14 64 — 2032-11-19
Nevanac
NEPAFENAC
 Harrow Health 3 60 — 2027-01-31

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7834059 Nevanac method of use 85 2027-01-31
8946292 Arthrotec method of use 80 2027-03-22
8871809 Arthrotec method of use 80 2027-10-17
8563613 Arthrotec method of use 80 2027-10-17
8252838 Arthrotec method of use 80 2028-04-21
9539335 Arthrotec method of use 75 2027-10-17
9132110 Arthrotec method of use 75 2027-10-17
9220784 Arthrotec method of use 75 2027-10-17
9168305 Arthrotec method of use 75 2027-10-17
9339551 Arthrotec method of use 75 2027-10-17

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10537585 Decadron formulation 25 2037-12-18
10159683 Decadron formulation 25 2034-05-23
9393213 Lotemax formulation 25 2033-05-03
10646437 Lotemax formulation 25 2033-05-03
10646436 Lotemax formulation 25 2033-05-03
10688045 Lotemax formulation 25 2033-05-03
9393213 Lotemax formulation 25 2033-05-03
10688045 Lotemax formulation 25 2033-05-03
10799642 Decadron formulation 31 2032-05-11
8409606 Decadron formulation 31 2030-05-14

Related